{
  "relevance_rule": {},
  "priority_rules": [
    {
      "priority": "Very High",
      "rule_text": "Sessions containing more than 3 High Priority Keywords (from client list: Competitors, MRD, Companion Diagnostic, Therapy Selection, Liquid Biopsy, ctDNA, cfDNA, Biomarker Combinations/studies, and all High priority keywords in client list)",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "Competitors",
          "MRD",
          "Companion Diagnostic",
          "Therapy Selection",
          "Liquid Biopsy",
          "ctDNA",
          "cfDNA",
          "Biomarker Combinations",
          "Biomarker studies",
          "BostonGene",
          "Caris",
          "Caris Assure",
          "Circulogene",
          "Companion Diagnostic Development",
          "cfDNA",
          "Circulating Tumor DNA",
          "Exact Sciences",
          "Exai Bio",
          "Foresight",
          "Foundation Medicine",
          "FoundationOne",
          "FoundationOne CDx",
          "FoundationOne Liquid",
          "FoundationOne Liquid CDx",
          "FoundationOne Tracker",
          "Galleri",
          "GRAIL",
          "Illumina",
          "InVisionFirst",
          "Invitae",
          "Liquid Biopsy",
          "Lucence",
          "LUNAR-2",
          "Minimal Residual Disease",
          "Myriad Genetics",
          "Natera",
          "Neogenomics",
          "OncoExtra",
          "Oncomap",
          "Personalis",
          "Precede Biosciences",
          "RaDar",
          "SHIELD LUNG",
          "Shield",
          "Signatera",
          "SAGA Diagnostics",
          "Tempus",
          "Tempus xF",
          "Tempus xF+"
        ],
        "categories": [
          "Target Companies",
          "Competitor Product",
          "Application",
          "Diagnostics",
          "TrialEndPoint",
          "Product"
        ],
        "contextual_concepts": []
      },
      "exclusions": [
        "Internal",
        "Not Relevant"
      ],
      "reasoning": "This rule is a priority assignment rule using keywords approach, as it is based on the count of high priority keywords from the client list. Sessions must contain more than 3 of these keywords to be assigned 'Very High' priority. Excludes 'Internal' and 'Not Relevant' keywords/categories."
    },
    {
      "priority": "High",
      "rule_text": "Sessions containing any of the following: Competitors, MRD, Companion Diagnostic, Therapy Selection, Liquid Biopsy, ctDNA, cfDNA, Biomarker Combinations/studies, or any High priority keyword from client list, but not qualifying for 'Very High' priority (i.e., contains 1-3 High priority keywords only)",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "Competitors",
          "MRD",
          "Companion Diagnostic",
          "Therapy Selection",
          "Liquid Biopsy",
          "ctDNA",
          "cfDNA",
          "Biomarker Combinations",
          "Biomarker studies",
          "BostonGene",
          "Caris",
          "Caris Assure",
          "Circulogene",
          "Companion Diagnostic Development",
          "cfDNA",
          "Circulating Tumor DNA",
          "Exact Sciences",
          "Exai Bio",
          "Foresight",
          "Foundation Medicine",
          "FoundationOne",
          "FoundationOne CDx",
          "FoundationOne Liquid",
          "FoundationOne Liquid CDx",
          "FoundationOne Tracker",
          "Galleri",
          "GRAIL",
          "Illumina",
          "InVisionFirst",
          "Invitae",
          "Liquid Biopsy",
          "Lucence",
          "LUNAR-2",
          "Minimal Residual Disease",
          "Myriad Genetics",
          "Natera",
          "Neogenomics",
          "OncoExtra",
          "Oncomap",
          "Personalis",
          "Precede Biosciences",
          "RaDar",
          "SHIELD LUNG",
          "Shield",
          "Signatera",
          "SAGA Diagnostics",
          "Tempus",
          "Tempus xF",
          "Tempus xF+"
        ],
        "categories": [
          "Target Companies",
          "Competitor Product",
          "Application",
          "Diagnostics",
          "TrialEndPoint",
          "Product"
        ],
        "contextual_concepts": []
      },
      "exclusions": [
        "Internal",
        "Not Relevant",
        "More than 3 High Priority Keywords"
      ],
      "reasoning": "This is a priority assignment rule using keywords approach, for sessions with 1-3 High priority keywords. Excludes 'Internal', 'Not Relevant', and sessions qualifying for 'Very High' priority."
    },
    {
      "priority": "Medium",
      "rule_text": "Sessions containing any of the following: HRD, Tissue Biopsy, methylation, NGS, profiling/sequencing related keywords and applications, or any Medium priority keyword from client list, but not qualifying for 'High' or 'Very High' priority",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "HRD",
          "Homologous Recombination Deficiency",
          "Tissue Biopsy",
          "methylation",
          "DNA Methylation",
          "Epigenomics",
          "Fragmentomics",
          "Genetic Profiling",
          "Genomic Alterations",
          "Genomic Profiling",
          "Methylation",
          "Molecular Profiling",
          "Next Generation Sequencing"
        ],
        "categories": [
          "Biomarker",
          "Testing",
          "Application",
          "Diagnostics"
        ],
        "contextual_concepts": [
          "profiling",
          "sequencing"
        ]
      },
      "exclusions": [
        "High",
        "Very High",
        "Internal",
        "Not Relevant"
      ],
      "reasoning": "This is a priority assignment rule using keywords approach, for sessions with Medium priority keywords, excluding those qualifying for High or Very High priority."
    },
    {
      "priority": "Low",
      "rule_text": "Sessions containing any other keywords from client list not covered by Medium, High, or Very High priority rules",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "Assessment of Multi-type Cancer Using Ctdna",
          "Biomarker Discovery",
          "Biomarker Testing",
          "Blood Tumor Mutational Burden",
          "Blood-based Screening",
          "CIRCULATE US",
          "CIRCULATE-Japan",
          "COSMOS-CRC-01",
          "CPG Sites",
          "Enhanced Biomarker Analysis",
          "Freenome",
          "Longitudinal Monitoring",
          "Longitudinal Response",
          "Metholome",
          "ORACLE",
          "Post-Surgery Decision Making",
          "Precision Oncology",
          "Proteomics",
          "Reccurence Monitoring",
          "Residual Cancer",
          "Response monitoring",
          "Screening",
          "Surveillance",
          "Targeted Drug Development",
          "Targeted Interventional Therapy",
          "Tissue Informed",
          "Tissue Na\u00efve",
          "Tissue-free Test",
          "Tumor Evolution",
          "Tumor Fraction Score",
          "Tumor mutational burden"
        ],
        "categories": [
          "Trial",
          "Biomarker",
          "Diagnostics",
          "Diagnostic Measure",
          "Treatment",
          "Application"
        ],
        "contextual_concepts": []
      },
      "exclusions": [
        "Medium",
        "High",
        "Very High",
        "Internal",
        "Not Relevant"
      ],
      "reasoning": "This is a priority assignment rule using keywords approach, for sessions with Low priority keywords, excluding those qualifying for Medium, High, or Very High priority."
    }
  ]
}